Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Cytotoxic T lymphocyte stimulant

DRUG CLASS:

Cytotoxic T lymphocyte stimulant

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

No biomarker	Glioblastoma	No biomarker	Glioblastoma	DOC1021 Sensitive: B - Late Trials DOC1021 Sensitive : B	DOC1021 Sensitive: B - Late Trials DOC1021 Sensitive : B
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	GL-ONC1 Sensitive: B - Late Trials GL-ONC1 Sensitive : B	GL-ONC1 Sensitive: B - Late Trials GL-ONC1 Sensitive : B
MGMT unmethylation	Glioblastoma	MGMT unmethylation	Glioblastoma	cemiplimab-rwlc + INO-5401 + INO-9012 Sensitive: C3 – Early Trials cemiplimab-rwlc + INO-5401 + INO-9012 Sensitive : C3	cemiplimab-rwlc + INO-5401 + INO-9012 Sensitive: C3 – Early Trials cemiplimab-rwlc + INO-5401 + INO-9012 Sensitive : C3
MYB underexpression	Adenoid Cystic Carcinoma	MYB underexpression	Adenoid Cystic Carcinoma	tretinoin Sensitive: C3 – Early Trials tretinoin Sensitive : C3	tretinoin Sensitive: C3 – Early Trials tretinoin Sensitive : C3
NOTCH1 mutation	Adenoid Cystic Carcinoma	NOTCH1 mutation	Adenoid Cystic Carcinoma	tretinoin Sensitive: C3 – Early Trials tretinoin Sensitive : C3	tretinoin Sensitive: C3 – Early Trials tretinoin Sensitive : C3
WT1 overexpression	Myelodysplastic Syndrome	WT1 overexpression	Myelodysplastic Syndrome	cytarabine + decitabine + tretinoin Sensitive: C3 – Early Trials cytarabine + decitabine + tretinoin Sensitive : C3	cytarabine + decitabine + tretinoin Sensitive: C3 – Early Trials cytarabine + decitabine + tretinoin Sensitive : C3
TP53 mutation	Myelodysplastic Syndrome	TP53 mutation	Myelodysplastic Syndrome	cytarabine + decitabine + tretinoin Sensitive: C3 – Early Trials cytarabine + decitabine + tretinoin Sensitive : C3	cytarabine + decitabine + tretinoin Sensitive: C3 – Early Trials cytarabine + decitabine + tretinoin Sensitive : C3
ASXL1 mutation	Myelodysplastic Syndrome	ASXL1 mutation	Myelodysplastic Syndrome	cytarabine + decitabine + tretinoin Sensitive: C3 – Early Trials cytarabine + decitabine + tretinoin Sensitive : C3	cytarabine + decitabine + tretinoin Sensitive: C3 – Early Trials cytarabine + decitabine + tretinoin Sensitive : C3
PML-RARA fusion	Acute Promyelocytic Leukemia	PML-RARA fusion	Acute Promyelocytic Leukemia	tretinoin + arsenic trioxide Sensitive: C3 – Early Trials tretinoin + arsenic trioxide Sensitive : C3	tretinoin + arsenic trioxide Sensitive: C3 – Early Trials tretinoin + arsenic trioxide Sensitive : C3
IDH1 mutation + ATRX deletion + TP53 deletion	Glioma	IDH1 mutation + ATRX deletion + TP53 deletion	Glioma	CAN-3110 Sensitive: D – Preclinical CAN-3110 Sensitive : D	CAN-3110 Sensitive: D – Preclinical CAN-3110 Sensitive : D